Skip to content
Clinical Trials – home
Therapeutic area

Congenital, familial and genetic disorders – page 55

  • 796 clinical trials
  • 308 recruiting
  • 374 conditions
  • 27 countries

Conditions in this area

374 conditions with trials, the busiest first

Clinical trials in Congenital, familial and genetic disorders

796 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

796 clinical trials

Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Atropine Sulfate
  • Sponsor:eyeDNA Therapeutics
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Tominersen
  • Sponsor:F. Hoffmann-La Roche AG

Neurofibromatosis+1

Not recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Selumetinib
  • Sponsor:AstraZeneca AB
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tazemetostat
  • Sponsor:Epizyme Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amiloride
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Codeine Phosphate
  • Sponsor:Moderna Therapeutics Inc.
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Doconexent
  • Sponsor:Ultragenyx Pharmaceutical Inc.
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ripasudil
  • Sponsor:Kowa Research Institute Inc.

Alexander disease

Not recruiting
Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:2'-O-(2-Methoxyethyl)-D-Ribose Antisense Oligonucleotide Targeting Glial Fibrillary Acidic Protein Messenger Ribonucleic Acid
  • Sponsor:Ionis Pharmaceuticals Inc.
Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Modified Mrna Encoding Human Methylmalonyl-Coenzyme A Mutase Containing A Polymorphism At Position 671
  • Sponsor:Moderna Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Congenital, familial and genetic disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.